» Articles » PMID: 29562234

The Protein Histidine Phosphatase LHPP is a Tumour Suppressor

Abstract

Histidine phosphorylation, the so-called hidden phosphoproteome, is a poorly characterized post-translational modification of proteins. Here we describe a role of histidine phosphorylation in tumorigenesis. Proteomic analysis of 12 tumours from an mTOR-driven hepatocellular carcinoma mouse model revealed that NME1 and NME2, the only known mammalian histidine kinases, were upregulated. Conversely, expression of the putative histidine phosphatase LHPP was downregulated specifically in the tumours. We demonstrate that LHPP is indeed a protein histidine phosphatase. Consistent with these observations, global histidine phosphorylation was significantly upregulated in the liver tumours. Sustained, hepatic expression of LHPP in the hepatocellular carcinoma mouse model reduced tumour burden and prevented the loss of liver function. Finally, in patients with hepatocellular carcinoma, low expression of LHPP correlated with increased tumour severity and reduced overall survival. Thus, LHPP is a protein histidine phosphatase and tumour suppressor, suggesting that deregulated histidine phosphorylation is oncogenic.

Citing Articles

Research Progress of SGLT2 Inhibitors in Cancer Treatment.

Miao X, Zhang J, Huang W, Wang Y, Jin A, Cao J Drug Des Devel Ther. 2025; 19():505-514.

PMID: 39872633 PMC: 11771169. DOI: 10.2147/DDDT.S485755.


Single-Cell Transcriptomics Reveals STAT1 Drives LHPP Downregulation in Esophageal Squamous Cell Carcinoma Progression.

Chen X, Xu Z, Zhou W, Zhang L, Huang J, Bao D Technol Cancer Res Treat. 2024; 23:15330338241293485.

PMID: 39497541 PMC: 11536641. DOI: 10.1177/15330338241293485.


Long noncoding RNA steroid receptor RNA activator 1 inhibits proliferation and glycolysis of esophageal squamous cell carcinoma.

He M, Qi Y, Zheng Z, Sha M, Zhao X, Chen Y World J Gastrointest Oncol. 2024; 16(10):4194-4208.

PMID: 39473951 PMC: 11514674. DOI: 10.4251/wjgo.v16.i10.4194.


Deciphering STAT3's negative regulation of LHPP in ESCC progression through single-cell transcriptomics analysis.

Chen Y, Zheng Z, Wang L, Chen R, He M, Zhao X Mol Med. 2024; 30(1):192.

PMID: 39468431 PMC: 11520558. DOI: 10.1186/s10020-024-00962-0.


Histidine phosphatase-ferroptosis crosstalk modulation for efficient hepatocellular carcinoma treatment.

Qin Y, Ling X, Li Y, Wang J, Wang J, Rong Z J Nanobiotechnology. 2024; 22(1):622.

PMID: 39402673 PMC: 11476632. DOI: 10.1186/s12951-024-02918-2.


References
1.
Chen M, Liu Y, Varley P, Chang Y, He X, Huang H . High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. Cancer Res. 2015; 75(8):1645-56. PMC: 4401643. DOI: 10.1158/0008-5472.CAN-14-2147. View

2.
Neff C, Abkevich V, Packer J, Chen Y, Potter J, Riley R . Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression. Mol Psychiatry. 2008; 14(6):621-30. DOI: 10.1038/mp.2008.8. View

3.
Vijayakrishnan J, Kumar R, Henrion M, Moorman A, Rachakonda P, Hosen I . A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. Leukemia. 2016; 31(3):573-579. PMC: 5336191. DOI: 10.1038/leu.2016.271. View

4.
Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J . Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004; 113(12):1774-83. PMC: 420505. DOI: 10.1172/JCI20513. View

5.
Schulze K, Imbeaud S, Letouze E, Alexandrov L, Calderaro J, Rebouissou S . Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47(5):505-511. PMC: 4587544. DOI: 10.1038/ng.3252. View